Edition:
India

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

0.88USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$0.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
108,764
52-wk High
$3.40
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Evoke Pharma Requests Type A FDA Meeting To Plan For Resubmission Of Gimoti NDA
Thursday, 27 Jun 2019 

June 27 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REQUESTS TYPE A FDA MEETING TO PLAN FOR RESUBMISSION OF GIMOTI™ NDA.EVOKE PHARMA INC - TYPE A MEETING, IF GRANTED, IS EXPECTED TO OCCUR WITHIN THIRTY DAYS OF FDA'S RECEIPT OF MEETING REQUEST AND MEETING PACKAGE.  Full Article

Evoke Pharma Reports Q1 Loss Per Share $0.11
Thursday, 9 May 2019 

May 8 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.11.AS OF MARCH 31, 2019, COMPANY'S CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $4.0 MILLION.EVOKE PHARMA - BASED ON CURRENT OPERATING PLAN, CO'S EXISTING CASH AND CASH EQUIVALENTS, BELIEVE, WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q1 2020.  Full Article

Evoke Pharma Submits Response To FDA Review Letter For Gimoti NDA
Thursday, 14 Mar 2019 

March 14 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA SUBMITS RESPONSE TO FDA REVIEW LETTER FOR GIMOTI™ NDA.EVOKE PHARMA INC - REQUESTED A MEETING WITH FDA PRIOR TO PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF APRIL 1, 2019..EVOKE PHARMA INC - FDA MEETING WAS GRANTED AND WILL BE HELD ON MARCH 21, 2019..  Full Article

Evoke Pharma Reports Third Quarter 2018 Results
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.09.Q3 EARNINGS PER SHARE VIEW $-0.08 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $6.6 MILLION.  Full Article

Evoke Pharma Q2 Loss Per Share $0.14
Friday, 10 Aug 2018 

Evoke Pharma Inc ::EVOKE PHARMA REPORTS SECOND QUARTER 2018 RESULTS AND RECENT HIGHLIGHTS.Q2 LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.ANTICIPATE RECEIPT OF 74-DAY FDA FILING COMMUNICATION LETTER IN MID-AUGUST AND ASSIGNMENT OF PDUFA GOAL DATE.  Full Article

Evoke Pharma Q4 Loss Per Share $0.02
Thursday, 8 Mar 2018 

March 7 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.Q4 LOSS PER SHARE $0.02.INCLUDED IN NET LOSS FOR Q4 OF 2017 WAS GAIN OF ABOUT $2.3 MILLION DUE TO CHANGE IN FAIR VALUE OF WARRANT LIABILITY.AS OF DECEMBER 31, 2017, CO'S CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $7.7 MILLION.  Full Article

FDA Approves PDUFA Fee Waiver For Gimoti New Drug Application
Monday, 5 Mar 2018 

March 5 (Reuters) - Evoke Pharma Inc ::FDA APPROVES PDUFA FEE WAIVER FOR GIMOTI™ NEW DRUG APPLICATION.FDA GRANTED ITS REQUEST FOR SMALL BUSINESS WAIVER OF PDUFA FEE OF ABOUT $2.4 MILLION FOR ITS TREATMENT GIMOTI.COMPANY REMAINS ON TRACK TO FILE GIMOTI NDA NEXT QUARTER.LOOK FORWARD TO POTENTIAL U.S. PRODUCT LAUNCH IN 2019 OF GIMOTI.AS CO REVIEWS 2018 BUDGET, ABLE TO EXTEND CASH RUNWAY INTO OCTOBER 2018.  Full Article

Evoke Pharma Announces Discovery Of Sex-Based Pharmacokinetic Differences For Gimoti​
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA INC - ‍EVOKE ANNOUNCES DISCOVERY OF SEX-BASED PHARMACOKINETIC DIFFERENCES FOR GIMOTI​.EVOKE PHARMA - ANALYSIS OF PK DATA BY SEX REVEALED STATISTICALLY SIGNIFICANT DIFFERENCES IN EXPOSURE BETWEEN WOMEN & MEN GIVEN SAME METOCLOPRAMIDE DOSE​.EVOKE PHARMA INC - ‍COMPANY HAS FILED NEW PATENT APPLICATIONS RELATED TO DISCOVERY​.EVOKE PHARMA INC - ‍COMPANY NOW EXPECTS TO FILE GIMOTI NDA IN Q2 OF 2018​.  Full Article

Evoke Pharma reports Q3 loss per share $0.34
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article